Investigating the Long-Term Neurocognitive Outcomes and Quality of Life in Pediatric Survivors of Acute Lymphoblastic Leukemia Treated with Contemporary Risk-Adapted Chemotherapy Protocols

Prof. Sarah Mitchell, Dr. Daniel Roberts

Independent Researchers

Abstract

Acute lymphoblastic leukemia (ALL) stands as the most prevalent cancer in children, with significant advancements in risk-adapted chemotherapy protocols leading to survival rates surpassing 85–90% in developed regions. Although the elimination of prophylactic cranial radiation therapy (CRT) has lessened severe neurotoxicity, new findings indicate that long-term survivors who underwent chemotherapy-only treatments still face subtle yet ongoing neurocognitive challenges that can negatively impact health-related quality of life (HRQoL). These cognitive issues often involve difficulties with attention, processing speed, working memory, and executive functions, potentially appearing years after treatment ends. This research article compiles current evidence regarding the long-term neurocognitive and quality-of-life outcomes for pediatric ALL survivors treated with modern risk-adapted chemotherapy protocols. The review delves into the epidemiology, neurotoxicity mechanisms, methodological aspects of survivorship research, and new interventions designed to alleviate late effects. Additionally, the article introduces a conceptual model connecting treatment exposures, biological susceptibilities, and psychosocial factors to long-term cognitive and HRQoL outcomes. Our analysis reveals that while modern protocols significantly reduce severe neurocognitive consequences compared to older CRT-based treatments, survivors still face an elevated risk of subtle cognitive inefficiencies, academic difficulties, and psychosocial issues that collectively affect their long-term quality of life. Key predictors include methotrexate exposure, intrathecal chemotherapy, younger age at diagnosis, female gender, and socioeconomic status. Longitudinal research shows that early attention problems during treatment can develop into executive dysfunction in later survivorship. The article concludes by advocating for future survivorship care to incorporate personalized risk assessment, neurocognitive monitoring, and targeted rehabilitation strategies to enhance long-term outcomes. Suggested tables and figures are included to assist clinical researchers in designing future longitudinal cohort studies and outcome measurement frameworks.

Keywords

Acute lymphoblastic leukemia; Survivorship in pediatric cancer; Neurocognitive results; Life quality; Neurotoxicity from chemotherapy; Therapy tailored to risk; Long-term effects; Executive functioning; Research on survivorship; Pediatric oncology.